Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Elizabeth M. Hecht

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4746-8415; OpenAlex author ID A5045946118. Sources: ClinicalTrials.gov.

Their work

Papers
16 (first author 2, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 16

  1. Pancreatic Cancer Screening and Early Detection: Where Are We Now? Co-author DOI 10.1148/rg.250146↗
  2. Advancements in early detection of pancreatic cancer: the role of artificial intelligence and novel imaging techniques. Co-author DOI 10.1007/s00261-024-04644-7↗
  3. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Last author DOI 10.2214/ajr.24.32160↗
  4. Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs. First author DOI 10.2214/ajr.24.31151↗
  5. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  6. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  7. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  8. Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consor… Co-author DOI 10.2214/ajr.22.27859↗
  9. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Co-author DOI 10.1007/s00261-019-02289-5↗
  10. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  11. Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist. First author DOI 10.1007/s00261-017-1349-3↗
  12. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-017-3556-1↗
  13. Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma? Co-author DOI 10.1002/jmri.25581↗
  14. Imaging of pancreatic cancer: what the surgeon wants to know. Last author DOI 10.1016/j.clinimag.2016.10.002↗
  15. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Co-author DOI 10.1245/s10434-015-5034-x↗
  16. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable p… Co-author DOI 10.1002/cncr.29112↗

Trials 2

  1. Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection Principal investigator NCT01094626↗
  2. Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients Principal investigator NCT01094561↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Avinash R. Kambadakone · 8 shared papers, 2020–2026 · strength 1.35
  2. Zhen J. Wang · 6 shared papers, 2020–2026 · strength 1.04
  3. Chenchan Huang · 5 shared papers, 2022–2026 · strength 1.04
  4. Ajit Harishkumar Goenka · 4 shared papers, 2023–2026 · strength 0.86
  5. Samuel Joseph Galgano · 4 shared papers, 2023–2025 · strength 0.74
  6. Lyndon Luk · 5 shared papers, 2017–2025 · strength 0.70
  7. Erik V. Soloff · 5 shared papers, 2020–2025 · strength 0.66
  8. Michael D. Kluger · 6 shared papers, 2016–2025 · strength 0.59
  9. Linda Chi Hang Chu · 3 shared papers, 2023–2025 · strength 0.56
  10. Naveen M. Kulkarni · 4 shared papers, 2020–2024 · strength 0.50
  11. Priya Bhosale · 4 shared papers, 2020–2024 · strength 0.50
  12. Marc Zins · 4 shared papers, 2020–2025 · strength 0.48
  13. Joy Liau · 3 shared papers, 2022–2025 · strength 0.48
  14. John A. Chabot · 5 shared papers, 2015–2023 · strength 0.41
  15. Eric Peter Tamm · 3 shared papers, 2020–2023 · strength 0.31
  16. Olga Rachel Brook · 3 shared papers, 2020–2023 · strength 0.31
  17. Lorenzo Mannelli · 3 shared papers, 2020–2023 · strength 0.31
  18. Parag P. Tolat · 3 shared papers, 2020–2023 · strength 0.31
  19. Michael Hayden Rosenthal · 2 shared papers, 2023–2024 · strength 0.30
  20. Ott Le · 2 shared papers, 2023–2024 · strength 0.30
  21. Jin Peng He · 2 shared papers, 2023–2025 · strength 0.29
  22. Candice W. Bolan · 2 shared papers, 2023–2025 · strength 0.29
  23. Atif Zaheer · 2 shared papers, 2023–2025 · strength 0.29
  24. Richard Kinh Gian · 2 shared papers, 2023–2025 · strength 0.29
  25. Carlos F. Fernandez-del Castillo · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.